statistiche ricercatore

Continente	#
EU - Europa	636
NA - Nord America	574
AS - Asia	444
SA - Sud America	59
Continente sconosciuto - Info sul continente non disponibili	33
AF - Africa	25
OC - Oceania	2
Totale	1.773

Nazione	#
US - Stati Uniti d'America	548
IT - Italia	284
RU - Federazione Russa	161
SG - Singapore	146
CN - Cina	99
VN - Vietnam	70
BR - Brasile	41
DE - Germania	41
KR - Corea	34
HK - Hong Kong	31
IN - India	24
FI - Finlandia	22
IE - Irlanda	22
FR - Francia	21
GB - Regno Unito	18
ZA - Sudafrica	13
CA - Canada	10
LT - Lituania	10
SE - Svezia	10
NL - Olanda	8
PL - Polonia	8
ES - Italia	7
IQ - Iraq	7
JP - Giappone	7
AR - Argentina	6
AT - Austria	6
PK - Pakistan	6
MX - Messico	5
CZ - Repubblica Ceca	4
KE - Kenya	4
BD - Bangladesh	3
BE - Belgio	3
PE - Perù	3
PR - Porto Rico	3
SA - Arabia Saudita	3
TR - Turchia	3
AU - Australia	2
BG - Bulgaria	2
CL - Cile	2
IR - Iran	2
MA - Marocco	2
PY - Paraguay	2
RO - Romania	2
SN - Senegal	2
TH - Thailandia	2
TT - Trinidad e Tobago	2
UA - Ucraina	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BO - Bolivia	1
BZ - Belize	1
CI - Costa d'Avorio	1
CO - Colombia	1
CR - Costa Rica	1
EG - Egitto	1
GE - Georgia	1
GY - Guiana	1
HN - Honduras	1
HU - Ungheria	1
JM - Giamaica	1
KZ - Kazakistan	1
LV - Lettonia	1
MD - Moldavia	1
MY - Malesia	1
NI - Nicaragua	1
PH - Filippine	1
PT - Portogallo	1
SC - Seychelles	1
SK - Slovacchia (Repubblica Slovacca)	1
SO - Somalia	1
UY - Uruguay	1
UZ - Uzbekistan	1
VC - Saint Vincent e Grenadine	1
VE - Venezuela	1
Totale	1.740

Nome	#
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations	231
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro	204
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3	196
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2	191
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season	181
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy	175
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants	168
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination	166
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm)	161
Beyond single-agent therapy: synergistic drug combinations and HSPG-Binding compounds as innovative strategies against SARS-CoV-2 variants	100
Totale	1.773

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	20	0	0	0	0	1	10	0	4	1	0	3	1
2023/2024	79	2	6	10	9	0	10	11	15	2	4	1	9
2024/2025	352	5	5	30	34	30	16	8	23	49	16	46	90
2025/2026	1.082	59	109	120	150	217	56	118	48	56	60	31	58
2026/2027	240	43	29	76	92	0	0	0	0	0	0	0	0
Totale													1.773